Information Provided By: 
Fly News Breaks for December 15, 2016
ZTS
Dec 15, 2016 | 06:25 EDT
Cowen analyst Steve Scala upgraded Zoetis to Outperform from Market Perform and raised its price target to $60 from $50 citing improved visibility and valuation. The analyst said the animal health market remains a compelling growth industry with fewer overhangs, Zoetis remains the market leader with in-line to above market revenue growth and higher earnings growth prospects, profitability has improved with manufacturing efficiencies still ahead, and potential M&A among competitors may lead to dislocation which Zoetis can capitalize on.
News For ZTS From the Last 2 Days
ZTS
Apr 23, 2024 | 05:05 EDT
Barclays lowered the firm's price target on Zoetis to $230 from $260 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst expects the Q1 reports to provide continuing evidence of improvement in generics and biosimilars for the specialty pharmaceuticals group.
